Plus Therapeutics (PSTV) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Plus Therapeutics Inc (PSTV) reports promising clinical progress and strategic funding, despite financial hurdles in its ...

Small-Cap Firms Dominate Thursday’s Gains. In this article, we are going to take a look at where Plus Therapeutics Inc.

Investment analysts at HC Wainwright issued their FY2029 earnings estimates for Plus Therapeutics in a research report issued to clients and investors on Friday, March 28th. HC Wainwright analyst S.

Plus Therapeutics, Inc.’s PSTV share price has dipped by 23.03%, which has investors questioning if this is right time to buy ...

Plus Therapeutics shares are trading higher by 183% during Thursday's session. The company announced that the FDA accepted ...

Analysts expect Plus Therapeutics to report an earnings per share (EPS) of $-0.51. The announcement from Plus Therapeutics is ...

H.C. Wainwright lowered the firm’s price target on Plus Therapeutics (PSTV) to $5.50 from $8 and keeps a Buy rating on the shares. The firm ...

Plus Therapeutics (NASDAQ:PSTV – Get Free Report) had its price target cut by analysts at HC Wainwright from $8.00 to $5.50 in a research report issued to clients and investors on Friday,Benzinga ...

Plus Therapeutics (PSTV) announces the U.S. Food and Drug Administration, FDA, has conditionally accepted the Company’s new proprietary name, ...